Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain
The primary purpose of the study is to evaluate the impact of treatment with fentanyl buccal
tablets on the anxiety symptoms commonly associated with chronic pain in patients with
breakthrough pain (BTP). Other purposes are to assess the management of BTP, to evaluate
patient functioning, and to determine any influences on the successful dose achieved.
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. Fentanyl Buccal
Tablet (FBT) is used for the treatment of BTP in adults with cancer who are already receiving
maintenance opioid therapy for chronic cancer pain. FBT treatment should be individually
titrated to an effective dose that provides adequate analgesia and minimizes undesirable
effects. To reach the safest effective dose for the individual patient as soon as possible,
the dose titration process is critical. The aim of this study, conducted under pragmatic
conditions in a large-scale population of cancer patients is to compare the proportion of
patients reaching an effective FBT dose after titration starting with either a 100 mcg dose
or a 200 mcg dose.
Safety of Dexmedetomidine in Severe Traumatic Brain Injury
The aim of this study is to assess the safety and feasibility of dexmedetomidine as an
adjunct to conventional sedative therapy compared to conventional sedative therapy alone in
patients with severe traumatic brain injury.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.